According to our latest study on Implantable Sensor Market Forecast to 2027 – COVID-19 Impact and Global Analysis – by Type, Application and End User, the market was valued at US$ 4,912.00 million in 2019 and it is projected to reach US$ 11,415.62 million by 2027; it is expected to grow at a CAGR of 11.1% during 2020–2027. The report highlights trends prevailing in the global implantable sensor market, and the factors driving and restraining the market growth.
Mobile healthcare technologies offer a great potential for improving patient care and reducing healthcare costs. Implantable and wearable technologies subsidize to a transformation in the mobile health era in terms of improving healthcare and health outcomes and providing real-time management on enhanced health management and tracking. Further, mobile technologies are paving the way for revolutionizing the diagnosis of diseases and monitoring patient treatment. Mobile sensors are helping in everything from monitoring our movements and sleeps to record the electrical activity in our hearts 24/7 as we go about our daily routines. As a result, the technology is quickly becoming vital for researching ways to cure illness and improve health.
The Sample Pages Showcases Content Structure and Nature of Information Included in This Research Study Which Presents A Qualitative and Quantitative Analysis: https://www.theinsightpartners.com/sample/TIPRE00016982/
Most cardiac rhythm management companies have applications that physicians and device technicians can access to track their patients with pacemakers and implantable cardioverter defibrillators, enrolled in remote patient management programs. All current-generation cardiac rhythm management devices are capable of remote transmission. Newer pacemakers and implantable cardioverter-defibrillators have Bluetooth LE transmission capability to create a straightforward way to share device data to patient-centered applications. As all cardiac rhythm management companies have built secure data platforms to receive remotely transmitted implanted device data, there is an opportunity to expand these platforms and include patient-facing software applications. The new generation of implantable hemodynamic sensors for heart failure management provides web- and app-based data to physicians to allow for physician-directed patient self-management of remotely transmitted intracardiac pressures.
Implantable devices or electronics have rapidly entered the area of digital health in various biomedical applications, including monitoring, tracking, and recording the vital signs of people to improve their health and that of their family.
Based on type, the global implantable sensor market is segmented into glucose sensor, temperature sensor, oxygen sensor, pressure sensor, and others. In 2019, the glucose sensor segment accounted for the highest share of the market. The growth for this segment is attributed to growing cases of diabetes coupled with increasing adoption of continuous glucose monitoring (CGM) devices.
Based on application, the implantable sensor market is segmented into medical diagnostic, clinical therapy, personal healthcare, and imaging. The medical diagnostic segment held the largest share of the market in 2019; however, the personal healthcare segment is expected to register the highest CAGR in the market during 2020–2027.
Schedule A Pre-Sale Discussion with The Author Team in A Slot That You Prefer to Address Queries on Scope of The Study, Customization, Introduction to Research Methodology, Assistance on Technologies and Market Definitions: https://www.theinsightpartners.com/inquiry/TIPRE00016982/
Based on end user, the implantable sensor market is segmented into hospitals, clinics, and diagnostic center. The hospitals segment held the largest share of the market in 2019 and it is estimated to register the highest CAGR in the market during the forecast period. Hospitals serve a significant role by providing extensive range of medical services to the patient population suffering from a wide variety of diseases. This has increased the adoption of implantable biosensors in hospitals and clinics. This, combined with growing number of hospital admissions, is projected to drive the segment. This is expected to increase the treatment process for treating chronic conditions, which, in turn, is expected to increase the usage of implantable sensors in the hospitals.
The growth of the implantable sensor market is driven by increasing prevalence of chronic diseases and growing adoption of mobile healthcare technologies. However, low rate of adoption in emerging countries is the major factors hindering the market growth. Analog Devices, Inc.; DEXCOM, INC.; Glusense Ltd.; Honeywell International Inc.; Medtronic; NXP SEMICONDUCTORS N.V.; Pinnacle Technology Inc.; Sensirion AG; TE Connectivity; and Texas Instruments Incorporated are among the major companies operating in the market.
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
